New Genomic DNA Modification in Zebrafish Could Help Us Study Human Disease
https://pixabay.com/photos/danio-rerio-zebrafish-small-fish-4996610/

New Genomic DNA Modification in Zebrafish Could Help Us Study Human Disease

Did you know that zebrafish, a tropical freshwater fish, are being more commonly used to model and study human diseases? Now, says Phys.org, researchers from the Garvan Institute of Medical…

Continue Reading New Genomic DNA Modification in Zebrafish Could Help Us Study Human Disease
Sotatercept for PAH Granted Orphan Designation from EC
https://pixabay.com/illustrations/cup-champion-award-trophy-winner-1613315/

Sotatercept for PAH Granted Orphan Designation from EC

In a recent press release, biopharmaceutical company Acceleron Pharma, Inc. ("Acceleron") announced that its investigational drug candidate sotatercept received Orphan designation from the European Commission (EC) for the treatment of…

Continue Reading Sotatercept for PAH Granted Orphan Designation from EC
Phase 1b Data Shows Magrolimab Clinical Response for AML
source: pixabay.com

Phase 1b Data Shows Magrolimab Clinical Response for AML

In early December 2020, biopharmaceutical company Gilead Sciences, Inc. ("Gilead") shared updated results from a Phase 1b clinical trial evaluating magrolimab for patients with treatment-naïve acute myeloid leukemia (AML). Generally,…

Continue Reading Phase 1b Data Shows Magrolimab Clinical Response for AML
Could a Levodopa Enriched Tomato Be the Fix for Parkinson’s? 
https://pixabay.com/photos/tomato-food-eating-red-vegetable-1205699/

Could a Levodopa Enriched Tomato Be the Fix for Parkinson’s? 

If you've ever heard the term "levodopa" be discussed, it was probably in regards to Parkinson's disease. Currently, levodopa (L-DOPA) is the most commonly prescribed therapy for patients with Parkinson's.…

Continue Reading Could a Levodopa Enriched Tomato Be the Fix for Parkinson’s? 
ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency
Arcaion / Pixabay

ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency

In early December 2020, mRNA medicines company Arcturus Therapeutics Holdings Inc. ("Arcturus") announced that the company begun dosing participants within its Phase 1b clinical trial. Within the trial, researchers will…

Continue Reading ARCT-810 Dosing Begun in Phase 1b Trial for OTC Deficiency

An Introduction to JumpStart

Did you know The Orphan Disease Center (ODC, a center within the Perelman School of Medicine at the University of Pennsylvania) has a program to assist patient groups and families…

Continue Reading An Introduction to JumpStart